The simultaneous inhibition of RAS-MAPK and PI3K/AKT/mTOR in in vitro and in vivo NB models has demonstrated the synergistic effects between crizotinib and Torin2 (mTOR inhibitor) [133, 134] and has recently resulted in the opening of an early stage clinical trial to test the toxicity of a combined ALK and PI3K/AKT/mTOR inhibitors treatment. The gene discussed is ALK; the disease is neuroblastoma.